SCHEMBL7220982

SCHEMBL7220982

CCCOc1cccc2c1CC(CN1CCC(c3c[nH]c4ccc(F)cc34)CC1)C2

nearest known ligand 0.58

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 3/20 0.58
OPRK1 P41145 3/20 0.58
OPRL1 P41146 3/20 0.58
HTR1A P08908 11/20 0.55
HTR7 P34969 4/20 0.55
SLC6A4 P31645 7/20 0.48
DRD2 P14416 5/20 0.48
HTR2A P28223 3/20 0.44
HTR6 P50406 3/20 0.44
DRD1 P21728 1/20 0.44
HTR2C P28335 1/20 0.44
DRD3 P35462 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7220979 0.87 OPRM1 (0.59) OPRM1OPRK1OPRL1HTR1AHTR7
SCHEMBL7511639 0.86 DRD2 (0.45) OPRM1OPRK1OPRL1HTR1AHTR7
SCHEMBL14280674 0.74 OPRL1 (1.00) OPRM1OPRK1OPRL1HTR1AHTR7
SCHEMBL7511636 0.73 OPRM1 (0.43) OPRM1OPRK1OPRL1HTR1AHTR7
SCHEMBL7219355 0.71 ADRA1D (0.60) SLC6A4
SCHEMBL7818172 0.71 HTR1A (0.67) OPRM1OPRK1OPRL1HTR1AHTR7
SCHEMBL4673580 0.70 HTR1B (0.71) OPRM1OPRK1OPRL1HTR1ASLC6A4
SCHEMBL30908884 0.70 HTR1A (0.52) OPRM1OPRK1OPRL1HTR1AHTR7
SCHEMBL7483363 0.70 HTR1A (0.52) OPRM1OPRK1OPRL1HTR1AHTR7
SCHEMBL28715723 0.70 HTR1A (1.00) OPRM1OPRK1OPRL1HTR1AHTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6552044-B2 Dopamine receptors H. LUNDBECK A/S (DK) 2003-04-22 US disclosed
EP-0946542-B1 INDANE OR DIHYDROINDOLE DERIVATIVES LUNDBECK & CO AS H (DK) 2002-10-09 EP disclosed
US-6352988-B2 HIGH AFFINITY FOR D4 RECEPTORS; TREATMENT OF SCHIZOPHRENIA, OTHER PSYCHOSES, ANXIETY DISORDERS, DEPRESSION, ALCOHOL ABUSE, IMPULSE CONTROL DISORDERS, AGGRESSION H. LUNDBECK A/S (DK) 2002-03-05 US disclosed
US-20010021777-A1 Indane or dihydroindole derivatives H. LUNDBECK A/S (DK) 2001-09-13 US disclosed
US-20010020095-A1 Indane or dihydroindole derivatives H. LUNDBECK A/S (DK) 2001-09-06 US disclosed
US-6262087-B1 HAVE HIGH AFFINITY FOR D4 RECEPTORS; USEFUL IN THE TREATMENT OF CERTAIN PSYCHIATRIC AND NEUROLOGIC DISORDERS, INCLUDING PSYCHOSIS, DEPRESSION AND ANXIETY. H. LUNDBECK A/S (DK) 2001-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010020095-A1 Indane or dihydroindole derivatives HTR4, GPR4, GPR174 OPRM1 34/4885OPRK1 23/4885OPRL1 20/4885
US-20010021777-A1 Indane or dihydroindole derivatives HTR4, GPR4, GPR174 OPRM1 34/4885OPRK1 23/4885OPRL1 20/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.